TIDMAMS
RNS Number : 3488U
Advanced Medical Solutions Grp PLC
01 August 2022
1 August 2022
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Directorate Change
Liz Shanahan Appointed as an Independent Non-Executive
Director
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS),
the world-leading specialist in tissue-healing technologies , is
pleased to announce that, as the next step in its communicated plan
to refresh the Non-Executive Directors on the Board, Liz Shanahan
will be appointed as an Independent Non-Executive Director with
immediate effect.
Liz is a life sciences entrepreneur with extensive experience
advising leading global pharmaceutical and healthcare organisations
on their communications. She is currently a Non-Executive Director
of Inspiration Healthcare Group plc and Celadon Pharmaceuticals plc
(previously Summerway Capital plc), both of which are AIM-listed.
Most recently, she was a Non-Executive Director of UDG Healthcare
plc, a company that was listed on the London Stock Exchange and a
constituent of the FTSE 250 up until its GBP2.8 billion takeover in
August 2021.
Until 2014, she was Global Head of Healthcare & Lifesciences
at the NYSE-listed management consultancy, FTI Consulting Inc.,
which in 2007 acquired the communications business Santé
Communications, founded by Liz in 1995. Liz is a Trustee of CW+,
the charitable arm of Chelsea & Westminster Foundation Trust
Hospital in London and a member of the organisation's Innovations
Advisory Board. Alongside her Board appointments she is a business
advisor and Executive coach.
Peter Allen, Chairman of AMS, said : "I am very pleased to
welcome Liz to the Board of AMS, who brings with her significant
experience in healthcare organisations, as well as specialist
skills in communication and Executive coaching. She will be an
extremely valuable addition to our Board."
Liz Shanahan commented : "I have been watching AMS's progress
closely during my career and am very excited to be joining the
Board of such a high-quality Company."
Liz will immediately join the Audit, Nomination and Remuneration
Committees and will be responsible for Workforce Engagement in line
with the UK Corporate Governance Code requirements. The composition
of each of the Board Committees from 1 August 2022 is therefore
confirmed as follows:
Board Committee Membership
Audit Committee Grahame Cook (Chairman)
Douglas Le Fort
Liz Shanahan
---------------------------
Nomination Committee Peter Allen (Chairman)
Grahame Cook
Douglas Le Fort
Chris Meredith
Liz Shanahan
---------------------------
Remuneration Committee Douglas Le Fort (Chairman)
Peter Allen
Grahame Cook
Liz Shanahan
---------------------------
The following information is disclosed pursuant to Schedule Two,
paragraph (g) of the AIM Rules for Companies:
Elizabeth Ann Shanahan (age 57) holds or has held Directorships
and partnerships in the five years preceding her appointment at AMS
as follows:
Current Directorships Previous Directorships
Celadon Pharmaceuticals plc Chelsea & Westminster Hospital
(previously Summerway Capital NHS Foundation Trust
plc)
-------------------------------------
Inspiration Healthcare Group UDG Healthcare plc
plc
-------------------------------------
Akusus Holdings Ltd Connected Tech Group Ltd (previously
Captive Health Limited)
-------------------------------------
CWPlus (Director and Trustee) Kingdom Clinics Limited
-------------------------------------
Onetouchtelecare Limited Kingdom R&D Ltd
-------------------------------------
Kingdom Therapeutics Limited Kingdom Laboratories Ltd
-------------------------------------
Sante Healthcare Consulting
Ltd
-------------------------------------
No further information in connection with her appointment is
required to be disclosed under Schedule Two, paragraph (g) of the
AIM Rules for Companies.
-End -
For further information, please visit www.admedsol.com or
contact:
Advanced Medical Solutions Group plc Tel: +44 (0) 1606
545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Michael King, Investor Relations
Consilium Strategic Communications Tel: +44 (0) 20 3709
5700
Mary-Jane Elliott / Matthew Neal / Matthew AMS@consilium-comms.com
Cole
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597
5970
Daniel Adams / Gary Clarence
HSBC Bank PLC (Broker) Tel: +44 (0) 20 7991
8888
Sam McLennan / Joe Weaving / Stephanie
Cornish
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of
innovative tissue-healing technology, focused on quality outcomes
for patients and value for payers. AMS has a wide range of surgical
products including tissue adhesives, sutures, haemostats, internal
fixation devices and internal sealants, which it markets under its
brands LiquiBand(R) , RESORBA(R) , LiquiBandFix8(R) and Seal-G(R) .
AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal(R) brand as well as under
white label. Since 2019, the Group has made four acquisitions:
Sealantis, an Israeli medical device company with a
patent-protected sealant technology platform; Biomatlante, an
established French developer and manufacturer of innovative
surgical biomaterial technologies, Raleigh, a UK leading coater and
converter of materials predominately for woundcare and
bio-diagnostics products and AFS Medical, a specialist distributor
of minimally invasive surgical devices based in Austria .
AMS's products, manufactured in the UK, Germany, France, Israel,
the Netherlands, and the Czech Republic, are sold globally via a
network of multinational or regional partners and distributors, as
well as via AMS's own direct sales forces in the UK, Germany, the
Czech Republic and Russia. The Group has R&D innovation hubs in
the UK, Germany, France and Israel. Established in 1991, the Group
has more than 700 employees. For more information, please see
www.admedsol.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAEANXFDESAEFA
(END) Dow Jones Newswires
August 01, 2022 02:00 ET (06:00 GMT)
Advanced Medical Solutions (AQSE:AMS.GB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Advanced Medical Solutions (AQSE:AMS.GB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024